STOCK TITAN
  1. Home
  2. Sec-filings
  3. KLRA
  4. [8-K] Kailera Therapeutics, Inc. Reports Material Event

Kailera Therapeutics (KLRA) closes $718.8M IPO and adopts new charter

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. completed its initial public offering, selling 44,921,875 shares of common stock, including 5,859,375 additional shares purchased by the underwriters, at $16.00 per share. The IPO generated gross proceeds of $718.8 million before underwriting discounts and expenses.

In connection with the IPO, Kailera filed a new amended and restated certificate of incorporation and adopted amended and restated bylaws. These governance changes increase authorized common stock to 800,000,000 shares, authorize 10,000,000 shares of undesignated preferred stock, create a classified board with three-year staggered terms, limit director removal to for-cause by a two‑thirds stockholder vote, restrict stockholder written consents, and add Delaware and federal court exclusive forum provisions for specified disputes.

Positive

  • Large equity raise completed: The IPO of 44,921,875 common shares at $16.00 per share generated $718.8 million in gross proceeds, materially strengthening Kailera Therapeutics’ capital base for future operations and growth initiatives.

Negative

  • None.

Insights

Kailera’s $718.8M IPO significantly boosts capital and locks in IPO-style governance protections.

Kailera Therapeutics completed its IPO of 44,921,875 common shares at $16.00 per share, for gross proceeds of $718.8 million. This is a substantial equity capital raise that can support drug development, trials, and operating needs, though specific uses are not detailed here.

The company simultaneously overhauled its charter and bylaws. Authorized common stock increased to 800,000,000 shares and 10,000,000 shares of undesignated preferred stock were created, giving the board flexibility for future financings or strategic structures, subject to market conditions and board decisions.

Governance provisions follow a typical IPO pattern: a classified board with staggered three‑year terms, director removal only for cause with a two‑thirds vote, advance notice requirements, no stockholder action by written consent, and Delaware and federal exclusive forum clauses. These features can make changes in control or stockholder campaigns more procedurally complex, so future governance dynamics will largely play out through annual meeting contests rather than written consents.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
IPO shares sold 44,921,875 shares Common stock issued in IPO including underwriters’ option
IPO share price $16.00 per share Public offering price for common stock in IPO
IPO gross proceeds $718.8 million Proceeds before underwriting discounts and expenses
Underwriters’ additional shares 5,859,375 shares Additional shares from full exercise of option
Authorized common stock 800,000,000 shares Common stock authorized under restated certificate
Authorized preferred stock 10,000,000 shares Undesignated preferred stock authorized for future issuance
Director removal threshold Two-thirds vote Stockholder vote required to remove directors for cause
classified board of directors financial
"establish a classified board of directors, divided into three classes"
advance notice financial
"require the advance notice of nominations for election to the board"
exclusive forum regulatory
"designate the Court of Chancery of the State of Delaware to be the sole and exclusive forum"
derivative actions regulatory
"including, but not limited to, derivative actions, suits or proceedings brought on behalf of the Company"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
--12-31 false 0002096997 0002096997 2026-04-20 2026-04-20
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): April 20, 2026

 

 

KAILERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-43233   99-3088927

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

180 Third Avenue, 4th Floor

Waltham, MA

   02451
(Address of principal executive offices)   (Zip Code)

(781) 317-0290

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbols

  

Name of each exchange

on which registered

Common Stock, $0.00001 par value per share   KLRA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 
 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock. The Company’s board of directors and stockholders previously approved the filing of the Restated Certificate to be effective immediately after the closing of the IPO.

The Restated Certificate amended and restated the Company’s prior amended and restated certificate of incorporation, as amended, in its entirety, to, among other things: (i) fix the authorized number of shares of common stock at 800,000,000 shares; (ii) eliminate all references to the previously existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Company’s board of directors in one or more series; (iv) establish a classified board of directors, divided into three classes, each of whose members will serve for staggered three-year terms; (v) provide that directors may be removed from office only for cause and only upon the affirmative vote of the holders of at least two-thirds of the Company’s capital stock entitled to vote thereon; (vi) require the advance notice of nominations for election to the board of directors or for proposing matters that can be acted upon at a stockholders’ meeting in the manner provided in the Company’s bylaws then in effect; (vii) eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting; (viii) designate the Court of Chancery of the State of Delaware to be the sole and exclusive forum for certain actions, including, but not limited to, derivative actions, suits or proceedings brought on behalf of the Company or actions, suits or proceedings asserting claims of breach of a fiduciary duty owed by any of the Company’s directors, officers or stockholders, provided that the exclusive forum provision will not apply to actions brought to enforce any liability or duty created by the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction; and (ix) designate the federal district courts of the United States of America to be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended.

The foregoing description of the amendments made by the Restated Certificate is qualified by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors, became effective. The Amended and Restated Bylaws amended and restated the Company’s prior bylaws in their entirety to, among other things: (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings; (ii) establish procedures relating to the nomination of directors; and (iii) conform to the amended provisions of the Restated Certificate.

The foregoing description of the amendments made in the Amended and Restated Bylaws is qualified by reference to the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

Item 8.01 Other Events.

On April 20, 2026, the Company completed its IPO of 44,921,875 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 5,859,375 additional shares, at a public offering price of $16.00 per share. The gross proceeds to the Company from the IPO were $718.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

   

Description

3.1    Restated Certificate of Incorporation of Kailera Therapeutics, Inc.
3.2    Amended and Restated Bylaws of Kailera Therapeutics, Inc.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    KAILERA THERAPEUTICS, INC.
Date: April 20, 2026     By:  

/s/ Ronald C. Renaud, Jr.

      Ronald C. Renaud, Jr.
      President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Kailera Therapeutics (KLRA) announce regarding its IPO?

Kailera Therapeutics completed its initial public offering of 44,921,875 common shares at $16.00 per share. This total includes 5,859,375 additional shares from the underwriters’ option, providing $718.8 million in gross proceeds before underwriting discounts and expenses.

How much capital did Kailera Therapeutics (KLRA) raise in its IPO?

Kailera Therapeutics raised gross proceeds of $718.8 million through its IPO. The company sold 44,921,875 shares of common stock at $16.00 per share, including full exercise of the underwriters’ option, before deducting underwriting discounts and offering expenses.

How many shares were sold in the Kailera Therapeutics (KLRA) IPO and at what price?

Kailera Therapeutics sold 44,921,875 shares of its common stock in the IPO at $16.00 per share. This figure includes 5,859,375 additional shares issued when underwriters fully exercised their option to purchase more shares from the company.

What changes did Kailera Therapeutics (KLRA) make to its certificate of incorporation?

Kailera adopted an amended and restated certificate of incorporation effective after the IPO closing. It increased authorized common stock to 800,000,000 shares, authorized 10,000,000 undesignated preferred shares, created a classified board, and added Delaware and federal exclusive forum provisions for specified disputes.

How did Kailera Therapeutics (KLRA) change its corporate governance structure?

Kailera implemented a classified board with three staggered classes and limited director removal to for-cause by a two-thirds stockholder vote. It also eliminated stockholder action by written consent, imposed advance notice rules for proposals, and aligned bylaws with its new restated certificate of incorporation.

What exclusive forum provisions now apply to Kailera Therapeutics (KLRA) stockholders?

Kailera designated the Delaware Court of Chancery as the exclusive forum for certain internal corporate disputes, including derivative actions and fiduciary duty claims. It also designated U.S. federal district courts as the exclusive forum for claims arising under the Securities Act of 1933.

Filing Exhibits & Attachments

5 documents

Other Documents